Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of biomarker combination in preparation of diagnostic reagent for fulminating myocarditis and medicine for fulminating myocarditis

A technology of biomarkers and diagnostic reagents, applied in drug combinations, biological tests, pharmaceutical formulations, etc., can solve problems such as difficulties in the diagnosis and treatment of fulminant myocarditis, insufficient risk assessment, etc., to reduce the level of biomarkers, strengthen diagnosis and Effect of follow-up treatment, improved efficiency and accuracy

Active Publication Date: 2022-04-29
TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH
View PDF8 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The present invention aims at the difficulty of diagnosing and treating fulminant myocarditis in the prior art and the problem of insufficient risk assessment, discovers a series of new biomarkers, and confirms their correlation with the onset of fulminant myocarditis, and two of them ( sST2 and CD163) as drug targets in alleviating and / or improving fulminant myocarditis; therefore, the detection of inflammatory factor levels through kits can be used to assist in the diagnosis of fulminant myocarditis or to evaluate the prognosis of fulminant myocarditis, and to control sST2 and CD163 through drugs level, in order to carry out more intensive diagnosis and follow-up treatment of the disease, which has great clinical application value

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of biomarker combination in preparation of diagnostic reagent for fulminating myocarditis and medicine for fulminating myocarditis
  • Application of biomarker combination in preparation of diagnostic reagent for fulminating myocarditis and medicine for fulminating myocarditis
  • Application of biomarker combination in preparation of diagnostic reagent for fulminating myocarditis and medicine for fulminating myocarditis

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0121] Increased expression levels of a large number of inflammatory factors in peripheral blood of patients with fulminant myocarditis

[0122] Study population and study design: From April 2017 to March 2019, inpatients with fulminant myocarditis were continuously enrolled in Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province. Inclusion criteria include: ①Aged over 18 years old; ②Diagnosed with fulminant myocarditis: Myocardial biopsy showed myocarditis or met the clinical diagnosis (rapid symptoms of severe hemodynamic disturbance, elevated cTnI, echocardiography showing a rapid decline in left ventricular EF value or less than 40%). Exclusion criteria include: ①acute myocardial infarction; ②common acute myocarditis; ③serious neurological diseases (Alzheimer's disease, advanced Parkinson's syndrome), lower limb mutilation or deaf-mute patients.

[0123] Detection of inflammatory factor expression profi...

experiment example 2

[0126] The expression levels of specific inflammatory factors in peripheral blood of patients with fulminant myocarditis improved after treatment decreased

[0127] Study population and study design: From April 2017 to March 2019, inpatients with fulminant myocarditis were continuously enrolled in Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province. Inclusion criteria include: ①Aged over 18 years old; ②Diagnosed with fulminant myocarditis: Myocardial biopsy showed myocarditis or met the clinical diagnosis (rapid symptoms of severe hemodynamic disturbance, elevated cTnI, echocardiography showing a rapid decline in left ventricular EF value or less than 40%). Exclusion criteria include: ①acute myocardial infarction; ②common acute myocarditis; ③serious neurological diseases (Alzheimer's disease, advanced Parkinson's syndrome), lower limb mutilation or deaf-mute patients.

[0128] Detection of inflammatory fac...

experiment example 3

[0131] The diagnostic and prognostic efficacy of specific inflammatory factors in peripheral blood for fulminant myocarditis

[0132] Study population and study design: From April 2017 to March 2019, inpatients with fulminant myocarditis were continuously enrolled in Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province. Inclusion criteria include: ①Aged over 18 years old; ②Diagnosed with fulminant myocarditis: Myocardial biopsy showed myocarditis or met the clinical diagnosis (rapid symptoms of severe hemodynamic disturbance, elevated cTnI, echocardiography showing a rapid decline in left ventricular EF value or less than 40%). Exclusion criteria include: ①acute myocardial infarction; ②common acute myocarditis; ③serious neurological diseases (Alzheimer's disease, advanced Parkinson's syndrome), lower limb mutilation or deaf-mute patients.

[0133]Detection of inflammatory factor levels: Peripheral blood was...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of a biomarker composition in preparation of a diagnostic reagent for fulminating myocarditis and a drug for fulminating myocarditis, belonging to the field of disease diagnostic reagents and drugs. The application is characterized in that the biomarker combination comprises Siglec-5, Siglec-5, Siglec-5, Siglec-5, Siglec-5 and Siglec-5, the combination of biomarkers is further selected from the group consisting of sST2, PAI-1, Siglec-5, CD163, CD40, P-Cadherin, CD14, and CTLA4, and the combination of biomarkers is selected from the group consisting of sST2, PAI-1, Siglec-5, CD163, CD40, P-Cadherin, CD14, and The invention finds that the expression of the biomarker in the plasma of a patient with the outbreak myocarditis is increased, and proves that the biomarker plays a role in diagnosing the outbreak myocarditis and the role of the biomarker as a drug target in relieving and / or improving the outbreak myocarditis, and the level of the biomarker can be detected, so that the application of the biomarker in the diagnosis of the outbreak myocarditis and the application of the biomarker in the treatment of the outbreak myocarditis can be realized. The biomarkers can be used for predicting and assisting in diagnosing the outbreak myocarditis or evaluating prognosis of the outbreak myocarditis, meanwhile, the level of the biomarkers is controlled through drugs, more intensified diagnosis and follow-up treatment can be carried out on diseases, and the biomarkers have huge clinical application value.

Description

technical field [0001] The invention belongs to the field of disease diagnostic reagents and medicines, and in particular relates to the application of biomarker combinations in the preparation of diagnostic reagents for fulminant myocarditis and medicines for fulminant myocarditis. Background technique [0002] Fulminant myocarditis is the most serious and special type of myocarditis. Its main features are sudden onset and extremely rapid progression of the disease. Patients will soon develop hemodynamic abnormalities, which may be accompanied by respiratory failure and liver and kidney failure. The early mortality rate is between above 50. [0003] The clinical characteristics and diagnosis and treatment status of fulminant myocarditis have the following characteristics: 1. The clinical understanding and diagnostic ability of fulminant myocarditis are seriously insufficient, resulting in a high rate of missed and misdiagnosed patients, and treatment is often delayed. 2. T...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/68G01N15/14A61K45/00A61P9/00
CPCG01N33/6887G01N33/6893G01N15/14A61K45/00A61P9/00G01N2800/325G01N2800/52G01N2800/60
Inventor 汪道文陈琛蒋建刚王金庄严李慧慧陈杨辉何梦颖
Owner TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com